 Methods: Prospective, comparative, randomized, double blind, controlled study. 15 patients with classic subfoveal choroidal neovascularization secondary to age-related macular degeneration were randomized. Group 1: receive PDT followed by 4 mg IVTA n7 or group 2: TT triple Therapy PDT followed by 4 mg IVTA 0.5 mg Ranibizumab n8.The main outcome measures were visual acuity VA, mean change in lesion size, mean change in foveal thickness, retreatment rate and the incidence and severity of adverse events. 